KOSDAQBiotech & Pharma263050

Eutilex

₩959 0.00%2026-11-18 close
Market Cap
₩35.3B
Turnover
₩0
Volume
0 shares
Shares out.
36.8M
PER
—
PBR
3.3×
EPS
-₩445
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses narrowing under court-led rehabilitation; listing status is the key test

Eutilex received a court order to start rehabilitation proceedings on March 30, 2026, so its listing status and business recovery are now the central questions, even though operating profit and net profit attributable to controlling shareholders turned positive in the third quarter of 2026.

  1. 1

    Operating loss narrowed from KRW 36.7 billion in 2022 to KRW 18.9 billion in 2025, and the company recorded losses in each of the four years from 2022 to 2025.

  2. 2

    Operating profit of KRW 65 million and net profit attributable to controlling shareholders of KRW 194 million in the third quarter of 2026 marked a swing to profit, yet quarterly revenue fell 64.8% year on year.

  3. 3

    The company filed for rehabilitation on February 24, 2026 and received the commencement order from the Seoul Rehabilitation Court on March 30, 2026.

  4. 4

    A disclaimer of opinion from the auditor triggered delisting grounds, and after an objection the Korea Exchange granted an improvement period through April 10, 2027.

  5. 5

    Total equity at the end of 2025 was KRW 15.8 billion, below paid-in capital of about KRW 18.4 billion, which places the company in a capital-impaired state, while the debt ratio rose from 15.0% in 2022 to 161.0% in 2025.

02

Business structure

Eutilex is a Kosdaq-listed immuno-oncology developer that was listed on December 24, 2018 and describes itself as a specialist in immuno-oncology drugs. Under the 2025 annual report, the consolidated operating segments are the bio segment, the IT segment and three biologics-manufacturing subsidiaries.

IT segment revenue was KRW 8,533,992 thousand in 2025 against KRW 2,130,423 thousand for the bio segment, so the IT segment accounted for most segment revenue, and the 2024 pattern was similar. The company attributed 2025 IT revenue growth to equipment sales and software revenue recognized over time.

On the bio side, the company announced that its EU101 antibody received FDA clearance for a 1/2 phase trial in January 2021. EU103 is described as a dual-function antibody that targets macrophages and killer T cells at the same time.

The 204 (EBViNT) therapy is in a 1/2a trial for EBV-positive lymphoma and solid tumors. An Armored CAR-T program is also in clinical testing, and the annual report states that the CAR-T production facility has been completed.

Against global drugmakers such as Pfizer and BMS, the company argues that its first-discovery technology gives it an edge. Peers in the same sector for comparison include Alteogen, ABL Bio and LigaChem Biosciences.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩3.5B-₩3.8B−108.6%
2025Q4₩2.4B-₩5B−210.5%
2026Q1₩1.3B-₩2.6B−206.7%
2026Q2₩500M-₩2.2B−402.5%
2026Q3₩1.2B₩65,001,5935.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩200M-₩36.7B-₩34.5B−17032.8%−39.3%15.0%
2023₩100M-₩29.8B-₩27.7B−22622.8%−45.9%15.0%
2024₩9.5B-₩26.5B-₩29.2B−278.3%−73.0%56.6%
2025₩10.3B-₩18.9B-₩23.9B−183.8%−156.6%161.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a disclosed basis, revenue went from KRW 216 million in 2022 to KRW 132 million in 2023, a 39.0% decline, then jumped to KRW 9.53 billion in 2024, a 7,136.1% increase. Revenue reached KRW 10.3 billion in 2025, up 8.1% year on year, making 2025 the largest year in the 2022–2025 period.

Segment figures show that IT segment revenue rose sharply in 2024 and drove the change in the revenue mix. Operating loss was KRW 36.7 billion in 2022, KRW 29.8 billion in 2023, KRW 26.5 billion in 2024 and KRW 18.9 billion in 2025, a steady narrowing that still left the company in the red every year.

The company attributed the 2025 reduction to lower selling and administrative expenses from company-wide cost cuts and budget reductions, and said that a settlement of joint research costs with a subsidiary raised non-operating income.

Net loss attributable to controlling shareholders was KRW 34.5 billion in 2022, KRW 27.7 billion in 2023, KRW 29.2 billion in 2024 and KRW 23.9 billion in 2025, with the 2024 loss widening. Net loss including non-controlling interests was KRW 25.8 billion in 2025.

Operating margin was -17,032.8% in 2022 and -22,622.8% in 2023, when revenue was very small, and improved to -278.3% in 2024 and -183.8% in 2025.

The debt ratio rose from 15.0% in 2022 to 56.6% in 2024 and 161.0% in 2025, with total liabilities of KRW 25.4 billion and total equity of KRW 15.8 billion at the end of 2025, of which KRW 15.3 billion was attributable to controlling shareholders.

Operating cash outflow narrowed from KRW 29.9 billion in 2022 to KRW 14.1 billion in 2025.

On a quarterly basis, revenue fell from KRW 3.53 billion in the third quarter of 2025 to KRW 2.39 billion in the fourth quarter, KRW 1.25 billion in the first quarter of 2026 and KRW 535 million in the second quarter, before rebounding to KRW 1.24 billion in the third quarter, a 132.6% quarter-on-quarter increase but a 64.8% year-on-year decline.

Operating loss was KRW 3.84 billion, KRW 5.03 billion, KRW 2.59 billion and KRW 2.15 billion across the four quarters before the third quarter of 2026, when operating profit was KRW 65 million.

Net loss attributable to controlling shareholders peaked at KRW 11.5 billion in the fourth quarter of 2025, and the third quarter of 2026 showed net profit attributable to controlling shareholders of KRW 194 million.

The sum of net losses attributable to controlling shareholders over the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, was KRW 16.4 billion.

05

Industry analysis

Immuno-oncology and cell therapy, the field in which Eutilex competes, is a sector where clinical data and licensing deals drive company value.

In earlier press reports, the co-CEO said that licensing deals struck after a phase 1 trial carry much larger upfront payments relative to deal size than deals struck at the preclinical stage. The same reporting said the company would work to accelerate the phase 1 trial of its faster-moving 103 candidate.

The company also said it keeps licensing open as an option alongside clinical development. These statements come from older reports and are not tied to any current negotiation.

The company argues that EU101 is an original technology because it is built on the immune checkpoint-activating substance its founder discovered, placing it ahead of global drugmakers researching the same substance. That is the company's own comparison and not an independent assessment.

The field includes many listed biotech companies competing on mechanism differentiation, and peers in the same sector include Samsung Biologics, Celltrion, Alteogen and SK biopharmaceuticals.

Eutilex depends heavily on its IT segment for revenue, so its bio pipeline alone is not a complete basis for assessing the business. Two public-sector IT contracts signed in January 2026 support IT segment revenue in the near term.

06

Outlook

The nearest checkpoint is the progress of the rehabilitation proceedings. After the March 30, 2026 commencement order, management authority over operations and asset disposal passed to a court-appointed administrator, and shareholder meetings came under court supervision.

As a result, the 2026 annual general meeting was not held, and the company said it will approve financial statements under the enforcement decree of the External Audit Act. The timing of an approved rehabilitation plan depends on court proceedings and no date has been announced.

On the listing side, the auditor's disclaimer of opinion, citing a scope limitation and uncertainty about going-concern status, created delisting grounds, and the company filed an objection.

The Korea Exchange granted an improvement period through April 10, 2027, ten days after the statutory filing deadline for the next annual report, and that end date can shift if a filing extension or a waiver of the late-filing sanction is approved.

After the period ends, the company must submit an improvement plan implementation report within 15 business days. In the IT segment, two contracts signed in January 2026 run through November 30, 2027 and December 27, 2027, so delivery under these contracts is central to revenue.

On the bio side, the planned phase 2 entry for the 204 candidate and the phase 1 trial for the 103 candidate were set out in older reports, and their current status should be confirmed through company disclosures.

The next annual report is the 2026 business report, so the full-year 2026 operating margin and the capital-impairment status will be the next confirmation points. The company says its CAR-T production facility is complete, so trial pace and any licensing deal will be the other points to track.

07

Valuation

PER
—
PBR
3.3×
ROE
-87.7%
EPS
-₩445
BPS
₩292
Dividend per share
₩0

Because the company has posted net losses over the last four quarters, the price-to-earnings ratio cannot be calculated. The price-to-book ratio places the share price well above book value per share, a premium to net asset value.

Total equity of KRW 15.8 billion at the end of 2025 was below paid-in capital of KRW 18.4 billion, placing the company in a capital-impaired state, which weakens the usefulness of net-asset-based valuation. Dividends are not paid, so dividend yield offers little basis for comparison.

For a company under rehabilitation, valuation frameworks tend to depend on court progress and listing status more than on conventional earnings multiples.

The third-quarter 2026 profit is a single quarter and does not offset the KRW 16.4 billion cumulative net loss attributable to controlling shareholders over the last four quarters.

Reading valuation therefore requires checking whether quarterly profit carries into the full year and how the cost base changed while revenue fell.

The improvement in operating margin and the smaller operating cash outflow show a direction toward recovery, but without a stronger capital structure the price-to-book ratio can only be read with limits.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Narrowing losses and a swing to profit

Operating loss narrowed each year from KRW 36.7 billion in 2022 to KRW 18.9 billion in 2025. The third quarter of 2026 recorded operating profit of KRW 65 million and net profit attributable to controlling shareholders of KRW 194 million. The company attributed the 2025 reduction partly to lower selling and administrative expenses.

Pipeline and production base

According to the annual report, a clinical program based on Armored CAR-T technology is underway and the CAR-T production facility has been completed. The company also holds antibody candidates including EU101 and EU103. It has said licensing remains an option alongside its clinical work.

IT segment contract base

In January 2026 the company disclosed contracts worth KRW 1.31 billion and KRW 1.2 billion for the rebuilding of a public collection information system. The IT segment accounted for most of 2025 consolidated revenue. The contracts run through late 2027, which can serve as a near-term revenue base.

09

Bear factors

Rehabilitation and listing risk

The company received a commencement order for rehabilitation on March 30, 2026, and all items at the annual general meeting were left undecided. A disclaimer of opinion created delisting grounds, and after the objection the company received an improvement period through April 10, 2027. Uncertainty over listing status is the largest negative factor.

Capital impairment and debt burden

Total equity at the end of 2025 was KRW 15.8 billion, below paid-in capital of about KRW 18.4 billion. The debt ratio rose from 15.0% in 2022 to 161.0% in 2025, with total liabilities of KRW 25.4 billion. Operating cash flow remained negative at KRW 14.1 billion outflow in 2025.

Revenue decline and cumulative losses

Quarterly revenue fell from KRW 3.53 billion in the third quarter of 2025 to KRW 535 million in the second quarter of 2026, and the KRW 1.24 billion in the third quarter of 2026 was down 64.8% year on year.

Net loss attributable to controlling shareholders over the last four quarters totaled KRW 16.4 billion, with the largest quarterly loss of KRW 11.5 billion in the fourth quarter of 2025. Profit has appeared in only one quarter so far.

10

Risk factors

Listing and disclosure risk

An objection was filed after a disclaimer of opinion triggered delisting grounds, and the improvement period ends April 10, 2027. The end date can change if a filing extension or late-filing sanction waiver is approved.

In January 2026 the company was notified of a potential designation as an unfaithful-disclosure company, citing one reversed disclosure and three failures to disclose.

Legal process and funding risk

Under rehabilitation, management authority over operations and asset disposal has passed to an administrator, and shareholder meetings are subject to court supervision. The timing of an approved rehabilitation plan depends on court proceedings and no date has been set. Ongoing operating cash outflows could constrain funding options.

Pipeline and licensing risk

The bio pipeline is still in clinical development, so timing may shift with trial results and regulatory decisions. Licensing has been described in older reports, and whether any deal is signed and on what terms should be confirmed through current disclosures. Because revenue depends heavily on the IT segment, bio value may take time to show up as sales.

11

What to watch next

  1. Date TBD, tied to court proceedings

    Submission and approval of the rehabilitation plan. The timing of approval will shape business continuity and the prospects for maintaining the listing.

  2. March 31, 2027 statutory deadline (2026 annual report)

    The 2026 annual report will be the next check on full-year operating margin, capital-impairment status and the auditor's opinion.

  3. April 10, 2027 end of improvement period

    End date of the improvement period, which can change with a filing extension. An improvement plan implementation report is due within 15 business days after the period ends.

  4. Contract periods ending November 30 and December 27, 2027

    Delivery progress on the two IT contracts signed in January 2026, which indicates near-term revenue flow.

12

Overall view

On a disclosed basis, Eutilex narrowed its operating loss from KRW 36.7 billion in 2022 to KRW 18.9 billion in 2025, and posted operating profit and net profit attributable to controlling shareholders in the third quarter of 2026.

Quarterly revenue fell sharply over the same stretch, the profit has appeared in only one quarter, and net loss attributable to controlling shareholders over the last four quarters totals KRW 16.4 billion. Revenue depends heavily on the IT segment, while the bio pipeline remains in clinical stages.

The commencement of rehabilitation on March 30, 2026, the postponed annual general meeting, and the delisting objection following the disclaimer of opinion, with an improvement period through April 10, 2027, make listing status and business recovery the main variables.

Total equity at the end of 2025 was below paid-in capital, which places the company in a capital-impaired state, and the debt ratio rose to 161.0%. Operating cash outflows narrowed but continue.

Positive factors include the smaller loss, the third-quarter profit swing, the clinical pipeline and the IT contract base; negative factors include legal proceedings, the capital structure and falling revenue.

The next checkpoints are the approval timing of the rehabilitation plan, the 2026 annual report and the end of the improvement period on April 10, 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. kind.krx.co.kr
  2. topstarnews.net
  3. news.nate.com
  4. digitaltoday.co.kr
  5. m.news.nate.com
  6. news.nate.com
  7. innoforest.co.kr
  8. m.news.nate.com
  9. m.news.nate.com
  10. m.news.nate.com
  11. etoday.co.kr
  12. etoday.co.kr
  13. etoday.co.kr
  14. etoday.co.kr
  15. edaily.co.kr
  16. edaily.co.kr
  17. edaily.co.kr
  18. yakup.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis